Life Sciences Archive » April, 2021

Life Sciences - April, 2021

347 articles

• PE Firms Want Out Of Pot RICO Suit Against Harvest, Verano
• NY Panel Sustains 1933 Act Claims For 1st Time Post-Cyan
• COVID IP Waiver Plan At WTO Being Revised Amid 'Optimism'
• The Big Picture: Opioid MDL's 1st Bellwether Gets Underway
• Robbins Geller, Pomerantz To Lead AstraZeneca Investor Suit
• Mass. Judge Says Heart Monitor Patent Validity Isn't Clear Yet
• W.Va. Senators Bid Again For More Opioid Oversight
• 11th Circ. Questions Fla. Medical Pot License Law
• Judge Won't OK Coppertone Buyers' $2.25M False Ad Deal
• Bausch Lobs IP Suit At Mylan Over Planned Trulance Generic
• Health Hires: Istari Oncology, Dykema, Paul Hastings
• COVID Vaccine Maker, Cancer Biotech IPOs Total $231M
• CVS Hand Sanitizer Buyers Win Certification In False Ad Suit
• Bankruptcy Watchdog Bares Teeth At BigLaw In Purdue Ch. 11
• Drug Cos. In Opioid Bellwether Deny Any Duty To Halt Orders
• 5 Key Details As Clock Ticks Down To Opioid MDL's 1st Trial
• IP Forecast: PTAB Fee Bias Claims & Uggs At The Fed. Circ.
• Nebraska Sheriff Accused Of Breaking Law With Pot Lawsuit
• 2nd Circ. Revives Challenge To Nursing Home Inspection Rule
• AOP Orphan Wins €140M Award From Taiwanese Pharma Co.
• Array Biopharma, Investors Agree To $8.5M Settlement Deal
• Celgene Sues Hikma To Block Revlimid Generic
• FDA To Ban Menthol Cigarettes, Cigar Flavors
• Fed. Circ. OKs ITC Ruling That Bio-Rad Infringed 10x Patents
• House Reps Want State Pot Laws Protected In Budget
• Deals Rumor Mill: Carlyle, Ant Group, Freshworks
• 3 Firms Give Up $1M In Fees From Purdue Ch. 11
• Biden Speech Pitches Investments To 'Win 21st Century'
• Ex-Katten Atty Caught In Shkreli Fraud Gives Up Law License
• GSK Says Amgen Patent Decision Will 'Devastate' Innovation
• Opioid Ad Blitz Targeted Not Just Docs But Insurers: J&J Rep
• Judge With 'West Virginia Grit' Takes On 1st Opioid MDL Trial
• Rite Aid Shoppers Nab Partial Cert. In 'Rapid Release' Ad Fight
• Atlanta TV Station Escapes Doc's Suit Over Stem Cell Reports
• In Agency First, FDA Says Co. Failed To Submit Trial Data
• Pharma Cos. Can Expect Harsh Antitrust Scrutiny From Biden
• J&J, Imerys Beat $117M Talc Verdicts Over Flawed Testimony
• Baylor, Gensetix Agree To Drop Cancer Patent Fight For Good
• Long-Running MRI Patent Row Settles Days Before Ill. Trial
• Bayer Rips 'Pay To Appeal' Charge In 11th Circ. Roundup Case
• Pfizer Tells Court Allele Wrong On Hatch-Waxman Safe Harbor
• Dr. Reddy's Says Amarin Delaying Heart Drug Competition
• Justices' Restitution Order May Allow FTC-Surescripts Deal
• Chancery OKs Keker Van Nest $19.6M Fee In Shire Ruling
• Indivior Finalizes $300M Deal To End Suboxone Cases
• HHS Eases Prescribing Rules For Opioid Addiction Meds
• Endo Says FTC Is Overreacting To Latest Impax Opioid Deal
• Maine Says Medical Pot Rule Doesn't Flout Commerce Clause
• Esperion Settles Investors' Cholesterol Drug Row For $18M
• J&J Sales Rep.'s Suit Says Male Workers Treated Better
• Teva Calls DOJ Questions About Morgan Lewis Work Intrusive
• AGs Warn Against Sanctioning Calif. In Generics Pricing MDL
• Newborn Opioid Victim Group Says Purdue Docs Lack Info
• PTAB Slashes 2 Bio-Rad DNA Patents In 10X Genomics Fight
• Pet Products Maker, Distributor Agree To End Antitrust Suit
• PTAB Upholds Oral Imaging Patent Involved In Dental IP Row
• Mylan Can Deduct Patent Suit Legal Fees, Tax Court Says
• Coronavirus Regulations: A State-By-State Week In Review
• Fed. Circ. Says J&J Unit's HIV Treatment May Enter Duty-Free
• Colgate Urges 2nd Circ. To Reverse $300M ERISA Suit Loss
• The Pandemic's Bright Spots For Lawyers Who Are Parents
• CBD Co. Dodges Counterclaims From Ex-Consultant, For Now
• There Are Other Crises Too, Opioid Maker Argues
• After USPTO, Iancu Isn't Done Advocating For Patent System
• Dental Suppliers Settle Antitrust Dispute Ahead Of Trial
• Strong IP Protection A Priority For Current, Ex-USPTO Heads
• Pot Cos. Sue Miami Over Dispensary Permit Denial
• DOJ Wants More Info On Morgan Lewis' Glenmark, Teva Work
• Pfizer 'Bonus' Irks Judge In Bristol-Myers Cancer IP Dispute
• Amazon Wants Ex-Worker's Contract Claim Axed In Pot Row
• Tenn. Can Impose Abortion Rule For Now, 6th Circ. Rules
• COVID Vaccine Maker, Jessica Alba's Startup Launch IPOs
• Risk-Based Compliance Improves Cannabis M&A Prospects
• Biden To Divert AstraZeneca Materials To India
• Wachtell, S&C Direct $7B Deal For Specialty Chemicals Co. 
• Distributors Lose Pretrial Attack On W.Va. Opioid Damages
• EU Taking AstraZeneca To Court Over COVID Vaccine Supply
• FTC Calls In-House Ilumina Case As Important As Fed. Trial
• ​​​​​​​What Opioid Crisis? Drugmakers Test Bold Claim In Calif. Trial
• DC Circ. Struggles With FDA Stance Over Electric Shock Ban
• Chancery Awards BioPharm Co. $38M For Fraud-Tainted Deal
• Fed. Circ. Won't Rehear Amgen Drug Patent Fight
• Covidien Urges 1st Circ. To Reconsider Ex-Exec's Patent Win
• Pharma Co.'s $4.8M Investor Deal OK'd, But Fees Undecided
• How Tuna Antitrust Ruling Affects Job Bias Class Actions
• What High Court Is Considering In Assignor Estoppel Case
• Medical Device Biz Fight Mostly Belongs In Wis., Court Says
• UK Judge Won't Invalidate Alcon's Glaucoma Treatment Patent
• FDA Lifts Pause On J&J COVID Vaccine Following Panel Vote
• Health Hires: Nelson Mullins, Holmusk, Eledon
• Gilead, Shire Beat FCA Suits In NJ Over Marketing Programs
• Revise Mansfield Diversity Mandates To Also Benefit Veterans
• 11th Circ. Finds Expert Qualified In Suit Over Surgery Tool
• UK Litigation Roundup: Here's What You Missed In London
• IP Forecast: Supercell Preps For Another Clash With Gree
• Mo. Atty Agrees To Pay $137K To End SEC's Pot Fraud Suit
• Cooley-Led NeuroPace Raises $102M After Brief CFIUS Pause
• J&J's Chief Patent Atty Says COVID IP Waiver Won't Work
• Coronavirus Litigation: The Week In Review
• Gilead Whistleblower Dinged For Lost Texts In Kickbacks Suit
• Pot Co. Verano To Spend More Than $200M On Pa. Business
• Deals Rumor Mill: Toshiba, Discord, Oxford Nanopore
• 5th Circ. Finds Chemo Drug Hair Loss Claims Filed Too Late
• GenMark Investor Wants Records On $1.8B Roche Deal
• L'Oreal Won't Face 'Subjective' Claims In UMass Cream Suit
• Justices Eye Narrowing Bar On Patent Attacks, Not Ending It
• FDA Highlights Shortfalls At COVID-19 Vaccine Plant
• Cooley-Led Workplace Software Firm Leads Trio Of Tech IPOs
• 3rd Circ. Won't Revive Kodak Claims After Ch. 11 Discharge
• Pot Co. TerrAscend Picks Up Pa. Dispensaries In $70M Deal
• Impax, Endo Say FTC's Win Doesn't Help Opana Buyers
• What FTC Victory Means For Reverse Payment Settlements
• EPA Asked To Ban Pesticide After Species Harm Report
• Locke Lord Can't Ax $30M Malpractice Suit Under Anti-SLAPP
• AIG Prevails In Suit Over Coverage Of Clinic's $9M Abuse Deal
• Dana-Farber Asks High Court To Ignore Cancer IP Row
• 8th Circ. Backs Creighton's Win In Med Resident's Bias Suit
• GSK Engages In Systemic Age Discrimination, Suit Says
• Possible 'Showstopper' Ruling Looms In GSK Birth Defect Suit
• Fed. Circ. Tosses 'Unusual' Appeal On Menopause Drug IP
• Facing $50B Trial, Drugmakers Minimize Roles In Opioid Sales
• Judge Says Insolvency Protects Telehealth Co. From Sanction
• Biden Admin. Slammed For Nixing WTO Critical-Drug Proposal
• Philips' Chinese Rivals Can't Dodge Ill. Trade Secrets Suit
• Walgreens Hit With 'Pink Tax' Suit Over Hair-Loss Meds
• 7th Circ. Rules Insurer Has No Duty To Cover $3.3M TCPA Deal
• Pot Co. Jushi's M&A Tear Continues With $5M Buy In Ohio
• BentallGreenOak Raises $1.8B Europe Real Estate Fund
• FDA Faces Fresh Drug-Device Headaches After DC Circ. Loss
• FTC's Challenge To $8B Illumina Merger Shipped To Calif.
• Chicago Pushes For Opioid Trial But Pharma Wants More Time
• 5th Circ. Affirms Win For Sanofi In Chemo Hair Loss Suit
• GOP Reps Introduce Bill To Get Vaccines To Citizens First
• DLA Piper Adds Benefits, Exec Comp Partner From Cooley
• Mapping The Predicate Chain For Medical Device Approval
• Illumina Can't Shake Off Lab's Suit Over Use Of 'Illuminox'
• Profs, Orgs Tell Justices To Review Sham Litigation Exception
• 11th Circ. Panel Dubious Of Pfizer Marketing Challenge
• 2nd Circ. Won't Revive Off-Label Ad Suit Against Taro
• Jones Day Nabs Venable Trial Atty In LA
• Coronavirus Regulations: A State-By-State Week In Review
• Bankruptcy Litigation Could See More Third-Party Funding
• $50B Opioid Trial Starts With Warring Views Of Drug Marketing
• RelayHealth's $10M Deal In E-Prescription Antitrust Case OK'd
• LA City Atty Gets $1.2M Penalty, Injunction Against Vape Co.
• Chinese National Gets 33 Months For Lab Trade Secret Theft
• Sens. Want Expert Panel To Guide $100B Plan For R&D
• Fed. Circ. Ruling Won't Lead To Patents On DNA, Justices Told
• Walmart Punished In Opioid MDL For Discovery Defiance
• Ill. Dental Office Asks 7th Circ. To Revive COVID Coverage Bid
• Solar Tracking Co. Tops 4 IPO Launches Totaling $705M
• Royalty Pharma GC Says Law Limits Overcharge Payback
• McCarter & English Picks Up IP Attys From Mintz Levin
• Biotech Biz Founder's Exit Deal Fight Moves On In Chancery
• Wiggin & Dana Adds Life Sciences-Focused IP Partner
• States Must Factor Race In COVID-19 Vaccine Prioritization
• 5 Key Details As Drugmakers Face $50B Opioid Trial In Calif.
• Investors Get $17M To End Suit Over $446M Nutraceutical Buy
• Opana Buyers Point To FTC's 5th Circ. Win Against Impax
• Ex-Katten Atty's Retirement Accounts Can Be Garnished
• Quinn Emanuel, Other Firms Sue MiMedx Over Legal Fees
• Law360's Guide To Biden's Judicial Picks
• FDA Loses DC Circ. Appeal In Imaging Liquid Regulation Fight
• Late Bid For New Suboxone Antitrust Complaint Falls Flat
• Allele Urges Court Not To Toss IP Suit Over Pfizer Vaccine
• AstraZeneca Notches FTC Approval For $39B Alexion Deal
• 5 Firms Lead Trio Of Biotech IPOs Raising $721M Combined
• WFH And DIY May Spell Uptick In Consumer Product Suits
• Lessons From Federal Fraud Charges Against UBiome
• EPA OIG Says Trump Admin. Hid Health Risks From Ill. People
• AdventHealth Seeks $1.5M After PPE Fraud Settlement Default
• Why The Future Law Firm Model Is Industry-Based Offerings
• 9th Circ. Shows How Stats Shore Up Rejection Of Class Cert.
• Health Hires: Sheppard Mullin, Oncternal Therapeutics
• Biden Tops 100 Vacancies As Pa. Judge Takes Senior Status
• CBD Maker Says Ex-Partners Can't Land Quick Win In IP Row
• 6 D&O Provisions To Consider When Buying SPAC Insurance
• UK Litigation Roundup: Here's What You Missed In London
• Relay Therapeutics Inks Up To $270M Drug Discovery Co. Buy
• What To Watch As Justices Eye Restriction On Patent Attacks
• Manatt Phelps Vet, A Top Biden Health Pick, Hits Capitol Hill
• Roche Challenges $171M Patent Judgment At Federal Circuit
• Pharma Co. Says PE Firm Owes $6.7M After Merger
• Health Co. Fights Dismissal Bid For $5M Virus Coverage Suit
• IP Forecast: Ferring, Lupin To Face Off In Clenpiq Patent Trial
• Amgen Tells Full Fed. Circ. Antibody IP Ax Dooms Biologics
• How Companies Should Respond To Patent Diversity Bill
• Vein Filter Co. Slams 'Harassing' Financial Discovery Order
• Anesthesiology Org. Hit With Libel Suit Over Drug Articles
• 'New Breed' Of NPEs Spurs Increase In Patent Cases In Q1
• 3 Firms Assemble Thermo Fisher's $20.9B PPD Purchase
• 9th Circ. Urged To Revive Health Care Co.'s Trade Secrets Suit
• USPTO Launches Fast, Free Appeals On Virus Patent Apps
• Investor Notches Partial Win In Del. Suit For Biogen Records
• Surgical Co. Says Insurer's J&J Suit Coverage Is Still Disputed
• CDC Panel Punts On J&J Coronavirus Vaccine Pause
• Drug Exclusivity Bill Meant To Help Generics Sent To Biden
• J&J Investors Urged To Reject CEO Pay Over Opioid Litigation
• Florida Grower Says Pot Co. Tilray Sabotaged Applications
• Miss. Medical Pot Measure Faces Fire From State Justices
• USTR Tai Hints At IP 'Modifications' To Aid Vaccine Rollout
• PharMerica Must Face FCA Claims Over Electronic Data
• Pharma Co. Sues Zurich Unit To Cover $30M In Spoiled Vials
• Defending Against 'Entrepreneurial Model' Class Actions
• Mass Tort Defendants Exploit Bankruptcy Rules To Avoid MDL
• NHS Fights To Revive £220M Drug Patent Suit At Top UK Court
• Enforcement Takeaways From ABA Antitrust Meeting
• 4th Circ. Revives Antitrust Suit Over Actelion's Drug Tracleer
• US Sees 'Very Similar' Issues In J&J, AstraZeneca Vaccines
• 5th Circ. Backs FTC In First Post-Actavis Pay-For-Delay Case
• IHS Beats Wash. Tribe's Health Costs Suit At DC Circ.
• SEC's Latest Guidance Likely To Further Slow SPAC Market
• Speculation Abounds As Biden Is Slow To Nominate FDA Head
• 4th Circ. Says 'Vagisan' TM Confusingly Similar To 'Vagisil'
• Abortion Pill Visit Rule Lifted During Pandemic
• Thought Leadership's Critical Role In Law Firm Diversity
• Lens Buyers Urge OK For $9.3M Fee Award In Price-Fix MDL
• Alsup Trims Drug Co. Investors' Cancer Treatment Study Suit
• Mallinckrodt Slams Bid To DQ Arnold & Porter In Its Ch. 11
• Coronavirus Regulations: A State-By-State Week In Review
• Claims Trimmed In Suit Over Faulty Vein Filter Implant
• Rare Blood Clots Prompt Pause Of J&J COVID Vaccine
• Biden Taps Lowenstein Sandler Atty, Ex-NJ AG To Run DEA
• False Ad Suit Against Stem Cell Clinic Back In Ga. State Court
• NJ Pot Regulators Prioritize Equity, Patients' Access
• Amgen Urges Justices To Leave Enbrel Patent Ruling Alone
• 7 Cos. Restock Pipeline With IPOs That Could Exceed $2.1B
• Rite Aid Beats Suit Over Ex-Atty's Insider Trading Warning
• Law360's 2021 Life Sciences Editorial Board
• The Right Approach To Personal Jurisdiction In Class Actions
• Minn. House Panel OKs Legalizing, Taxing Recreational Pot
• Where Health Care Enforcement Is Headed Under Biden
• Full 6th Circ. Set To Look At Tenn. Abortion Fight
• NJ Justices Won't Step Into 3rd Circ. Pelvic Mesh Fee Row
• Bayer Sued Over Flea And Tick Collars Tied To Pet Deaths
• Bang Energy Drink Maker Avoids Sanctions In False Ad Suit
• Ketone Supplement Co. Hits Rival With IP Suit
• SmileDirect Tells 9th Circ. 'Harassment' Continues In Calif.
• LA Fitness Launches $500M Fight Against 11 Insurers
• Drugmaker MannKind Escapes Investors' Suit At 9th Circ.
• NJ Judge Denies Class Cert. For Generic Lamictal Buyers
• Biden Seeks $132B For HHS In War Against COVID, Opioids
• 6th Circ. Upholds IRS Summons For Cannabis Biz Docs
• Perrigo Execs Ask Out Of Investor Lawsuit Over $1.9B Tax Bill
• Health Hires: Morgan Lewis, K&L Gates
• Parents Want Wholesaler Sanctioned In Drug Death Suit
• ​​​​​​​WTO Head Calls For More Vaccines To Developing Countries
• 4 Firms Guide Clinical Stage Pharma Cos. In $221M IPOs
• What Associates Should Consider Before Switching Practices
• Key Takeaways From FDA Warnings To CBD Cos.
• 3rd Circ. Revives LivaNova Bacteria Exposure Suit
• FTC Says Moving Illumina Suit To Calif. Is Risky Amid COVID
• Medical Pot Co. Sues Detroit Over School Zoning Decision
• Brenntag Agrees To Shell Out $2.3M To Wrap 401(k) Suit
• Wilson Sonsini Adds Ex-Shearman & Sterling Partner In Austin
• 9th Circ. 'Directly Supports' Zetia Class Fight, 4th Circ. Told
• Opioid Judge Withdraws After AbbVie Elevates His Atty Sister
• Scott + Scott To Rep Precigen Investors In Gas Fraud Suit
• Purdue Wants Another Month's Reprieve From Opioid Suits
• Real Estate Rumors: Ocean Bank, Blackstone, General Capital
• Minerva Calls Assignor Estoppel 'Ill-Conceived Atextual' Error
• Ambry Genetics Gets Data Breach Suit Axed, For Now
• Covidien Can't Score Patents From Ex-Worker, 1st Circ. Says
• Fed. Circ. Upholds No-Contempt Finding In Oxygen Mask Case
• Full Fed. Circ. Told Newer Amgen Drug Patent Was 'Trivial'
• Mitigating Anti-Kickback Risks Of Health Tech Stock Warrants
• Outdated Experts Doom Suit Tying Diabetes Drug To Cancer
• Execs Sued By SEC No 'Mailroom' Underlings, 1st Circ. Says
• Ex-CBD Exec Says Co. Shorted Pay, Skimped On Expenses
• Teva Unit Urges Fed Circ. To Revive ADHD Drug Row
• 4 Effective Ways To Prioritize Client Advocacy
• Lab Supplier Says Wrong Co. Sued Over Faulty COVID Tests
• FDA Letters Suggest Scrutiny Of Virus And Vaping Products
• Eversheds Sutherland Nabs IP Partner From Wilson Sonsini
• States Too Late To Question Report In MDL, Drugmakers Say
• Opioid MDL Judge Picks New Bellwethers, Denies Retaliating
• Ga. Talc Co. Says Strict Liability Claims Over Cancer Too Late
• Endo Hit With Default Judgment In Tenn. Opioid Baby Suit
• Fed. Circ. Judge Doubts ITC Erred In Microfluidic Chip Case
• Abortion Provider Secures Win To Block Activist's Videos
• Arkansas Mayor Sues Pot Co. Harvest Over Moved Grow
• 2nd Circ. Questions Takeda's 'Lazarus' Take On Drug Patents
• A Breakdown Of The PTAB Backlog Arthrex Caused
• Remote Law Firm Culture Should Prioritize Associate Training
• Illumina Hits Back At FTC, Says $8B Grail Deal Can Save Lives
• Locke Lord Asks Texas Panel To End $30M Malpractice Suit
• Goodwin Picks Up 3 New Partners In Antitrust, Life Sciences
• COVID Vaccine Hopeful Lands $100M In Funding Round
• 9th Circ. Finds Robot Surgery Suit Time-Barred
• Rite Aid Shopper Wants Class Cert. In 'Rapid Release' Ad Fight
• Business Groups Ask High Court To Review $2.1B J&J Verdict
• Fox News Must Face Ex-Ad Client's Accounting Scheme Suit
• Quest Says Ex-Amazon Worker's Medical Marijuana Suit Fails
• Calif. AG Says Sanctions Rec. 'Misunderstands' Generics MDL
• Election Yields 1st Union At Rhode Island Dispensary
• Walgreens Claims Crowell Betrayed It With Humana Suit
• Coronavirus Regulations: A State-By-State Week In Review
• Fed. Circ. Probes Alleged Misconduct In DNA Tech IP Fight
• Lax Contemporaneity Test Could Buoy Insider Trading Claims
• Mo. Says Pot Exec Can't Sue Over Residency Rules
• Ways Universities Can Improve Foreign Influence Compliance
• Virtual Litigation May Unravel The Narcissistic Lawyer
• Purdue Judge Wary Of Changing Reasons For Ch. 11 Probe
• FDA Alum Heads To Cooley Amid Active Life Sciences Scene
• Reaching The Post-Amgen High Bar For Antibody Patents
• AstraZeneca Escapes Suit Claiming Drug Caused Gangrene
• Ex-CMS Worker, DOJ Say Insider Trading Conviction Must Go
• 9th Circ. Revives Claims That Medtronic Skirted FDA Review
• Black-Owned IT Biz Says It Was Dumped From $10M Pa. Deal
• CVS Wants Tribe To Arbitrate Prescription Reimbursement Suit
• Colorado-Based Biotech Co. Grabs $150M In Series E
• Teva, Pharmacies Want Humana's Copay Fraud Claims Tossed
• Mallinckrodt Gets OK For Up To $35M In Exec Bonuses
• Fintech Seeks $2B Valuation In Latham, Davis Polk-Led IPO
• Biz Groups Flock To Support Appeal Of $75M Dicamba Verdict
• Justices Won't Revive Teva-IBSA Thyroid Drug Patent Fight
• 2 Ways High Court Could Reshape Patent Assignor Estoppel
• Illumina Wants FTC's Suit Over $8B Grail Deal Moved To Calif.
• Pharmacies Can't Escape More Trials In Opioid MDL
• Trulieve Acquires Pa. Pot Shops In $60M Deal
• ABA Remote Work Guide Raises Bar For Atty Tech Know-How
• How NY's Cannabis Legalization Act Prioritizes Equity
• Pharmacies Take Swipe At Judge Amid Tightening Opioid MDL
• Ill. Court Says Plastic Co. Must Pay For Chemical Plant
• AndroGel Makers, Buyers Clash Over FTC Getting Discovery
• Shkreli Balks At Ban From Leading Public Co., $1.4M Fine
• GAO Won't Revisit Ruling Backing VA Nuclear Medicine Deal
• Univ. Hospitals Say Positive COVID-19 Tests Trigger Coverage
• 'Ignore The Man Behind The Curtain' Won't Fly In COVID Suit
• Lateral Hire Conflict Screening Lessons From DLA Piper Case
• Health Hires: King & Spalding, Ropes & Gray
• Boston Drug Discovery Co. Grabs $75M In Series C
• 3rd Circ. Preview: Workplace, Insurance Rows Highlight April
• 11th Circ. Says Not Enough Evidence For Hysterectomy Suit
• National Black Farmers' Roundup Suit To Stay In Calif. MDL
• Vagisil Maker Gets Rival's 'Vagisert' TM Blocked At TTAB
• Big Pharma Tells Justices To Keep Assignor Estoppel
• Illumina Agrees To Delay $8B Grail Deal During FTC Challenge
• March IPOs Exploded, But The Boom Is Starting To Slow
• SEC, Ex-Katten Partner Reach Deal In Shkreli Fraud Suit
• Perrigo Hid $1.9B Tax Bill, Class Says In Seeking Fast Win
• Miss. High Court Won't Ax AG's J&J Talc False Ad Suit
• Bristol Myers Squibb Settles Medicaid Rebate Suit For $75M
• Ill. Court Says Suit Over Failed Shire Merger Rightly Tossed
• Deals Rumor Mill: Kioxia, Raizen, Bayer
• FDA Accused Of Brushing Off Safety Issues At Merck Plant
• SDNY Ruling Opens Door To Class Challenges In 2nd Circ.